HIV Vaccine for HIV

Phase 3

Waitlist Available

Research Sponsored by Agouron Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have never taken any anti-HIV drugs before.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing whether adding a vaccine to two drugs that are already used to treat HIV will be more effective than just using the two drugs.

Who is the study for?

This trial is for HIV-positive individuals who are at least 13 years old, have a viral load of at least 10,000 copies/ml and a CD4 count of over 250 cells/mm3. They must not have used any anti-HIV drugs previously. Minors need parental consent to participate.Check my eligibility

What is being tested?

The study is testing the effectiveness of adding an HIV vaccine called Remune to a standard drug regimen consisting of Combivir (zidovudine plus lamivudine) and nelfinavir in treating HIV infection.See study design

What are the potential side effects?

Potential side effects may include reactions at the injection site from Remune, as well as common antiretroviral side effects like nausea, headaches, fatigue, and possible changes in liver enzymes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have never taken any medication for HIV.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Agouron PharmaceuticalsLead Sponsor

16 Previous Clinical Trials

1,573 Total Patients Enrolled

Media Library

Combivir (zidovudine plus lamivudine) and nelfinavir (Antiretroviral Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00005002 — Phase 3

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: Combivir (zidovudine plus lamivudine) and nelfinavir Highlights & Side Effects. Trial Name: NCT00005002 — Phase 3

Combivir (zidovudine plus lamivudine) and nelfinavir (Antiretroviral Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005002 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

If I am interested, what are the requirements to sign up for this research opportunity?

"HIV positive individuals between the ages of 13 and 0 can apply to this clinical trial. The study seeks to enroll a total of 688 patients."

Answered by AI

How likely are patients to experience negative side effects from this medication?

"There is some efficacy data from Phase 3 clinical trials, as well as multiple rounds of data supporting safety, so our team at Power has given this treatment a score of 3 for safety."

Answered by AI